How Safe Are Universal Pluripotent Stem Cells?

González, Bryan J.; Creusot, Rémi J.; Sykes, Megan; Egli, Dieter

doi:10.1016/j.stem.2020.02.006

Cited by 15 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesize that any AF contains few 'hypoimmunogenic or universal hAFSCs' and many typical cells that are not hypoimmunogenic or universal hAFSCs and that hypoimmunogenic or universal hAF- Several researchers have considered developing universal or hypoimmunogenic hPSCs that do not express HLA Class Ia and Class II. [18][19][20][21][23][24][25][26][27][40][41][42][43][44] However, all of these methods except the method presented in our present study require knocking out, knocking in or editing specific genes, which indicate the need for genetic modification (editing) of the cells, which restrict the clinical use of the hPSCs. For example, several researchers reported knocking out or gene editing HLA-A, -B and/or -C genes to generate homozygous hPSCs.…”

Section: Discussionmentioning

confidence: 89%

Transient characteristics of universal cells on human‐induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 89%

Transient characteristics of universal cells on human‐induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources

et al. 2021

View full text Add to dashboard Cite

show abstract

“…65 However, this technology is nascent and has potential drawbacks, such as the unintended generation of transmissible cancers. 66…”

Section: Identif Ying Novel Mechanis Ms Of H Uman S K In Pl a S Ti mentioning

confidence: 99%

“…Several groups are working on gene‐editing strategies to make iPSCs invisible to the immune system; thus, creating universal donor cells that will avoid rejection 65 . However, this technology is nascent and has potential drawbacks, such as the unintended generation of transmissible cancers 66 …”

Section: Identifying Novel Mechanisms Of Human Skin Plasticity and Rementioning

confidence: 99%

Skin organoids: A new human model for developmental and translational research

Lee

Koehler

2021

Experimental Dermatology

View full text Add to dashboard Cite

Culturing skin cells outside of the body has been a cornerstone of dermatological investigation for many years; however, human skin equivalent systems typically lack the full complexity of native skin. Notably, skin appendages, such as hair follicles and sweat glands, remain a challenge to generate or maintain in cell cultures and reconstruct in damaged skin. Recent work from our lab has demonstrated methods for generating appendage-bearing skin tissue-known as skin organoids-from pluripotent stem cells. Here, we will summarize this work and other related works, and then discuss the potential future applications of skin organoids in dermatological research.

show abstract

“…Even if the generation of functional IPCs would be successful with the abovementioned cell types, allogeneic betalike cells could trigger the immune system of T1D patients resulting in graft rejection [15]. One strategy to make the IPCs invisible to the host immune system could be to generate universal stem cells by manipulating the genes that encode for human leukocyte antigen (HLA) class I and class II proteins [30,31]. Genetic modification approaches including the use of CRISPR/Cas9 gene-editing technology have also been used to eliminate the HLA gene expressions in iPSCs before differentiation into IPCs [32].…”

Section: Introductionmentioning

confidence: 99%

Tissue Engineering Strategies for Improving Beta Cell Transplantation Outcome

et al. 2021

View full text Add to dashboard Cite

Purpose of Review Beta cell replacement therapy as a form of islet transplantation is a promising alternative therapy with the possibility to make selected patients with type 1 diabetes (T1D) insulin independent. However, this technique faces challenges such as extensive activation of the host immune system post-transplantation, lifelong need for immunosuppression, and the scarcity of islet donor pancreas. Advancement in tissue engineering strategies can improve these challenges and allow for a more widespread application of this therapy. This review will discuss the recent development and clinical translation of tissue engineering strategies in beta cell replacement therapy. Recent Findings Tissue engineering offers innovative solutions for producing unlimited glucose responsive cells and fabrication of appropriate devices/scaffolds for transplantation applications. Generation of pancreatic organoids with supporting cells in biocompatible biomaterials is a powerful technique to improve the function of insulin-producing cell clusters. Fabrication of physical barriers such as encapsulation strategies can protect the cells from the host immune system and allow for graft retrieval, although this strategy still faces major challenges to fully restore physiological glucose regulation. Summary The three main components of tissue engineering strategies including the generation of stem cell-derived insulin-producing cells and organoids and the possibilities for therapeutic delivery of cell-seeded devices to extra-hepatic sites need to come together in order to provide safe and functional insulin-producing devices for clinical beta cell replacement therapy.

show abstract

How Safe Are Universal Pluripotent Stem Cells?

Cited by 15 publications

References 10 publications

Transient characteristics of universal cells on human‐induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources

Transient characteristics of universal cells on human‐induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources

Skin organoids: A new human model for developmental and translational research

Tissue Engineering Strategies for Improving Beta Cell Transplantation Outcome

Contact Info

Product

Resources

About